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-emain treatment available for restoration of the corneal endothelium is keratoplasty and DMEK provides faster visual recovery and
better postoperative visual acuity when compared to DSAEK. However, the technical challenges related to this technique and the steep
technical learning curve seem to prevent the overcoming of DSAEK in favor of DMEK. Furthermore, the outcome of lamellar
keratoplasty techniques is influenced by problems related to corneal grafting tissue availability, management, and quality. On the other
hand, improvements in the field of cell engineering have opened the way for the use of stem cells-derived corneal endothelial cells with
regenerative intent. In this overview, latest findings in endothelial cell engineering are reported, and perspectives of clinical application
of mesenchymal stem cells for corneal endothelial replacement and regeneration are evaluated.
1. Introduction
Currently, keratoplasty is themain solution for the treatment of
diseases involving corneal endothelium. Frequent indications
to endothelial corneal grafting include Fuchs’ endothelial
dystrophy, bullous keratopathy following phacoemulsification,
and endothelial disfunction after corneal transplant. Desce-
met’s membrane endothelial keratoplasty (DMEK), introduced
in 2006 [1], represents the most novel technique for endothelial
keratoplasty. It differs from Descemet’s stripping-automated
endothelial keratoplasty (DSAEK) for the use of a grafted
material that includes no corneal stroma but only endothelium
and Descemet membrane. -e graft can thus be introduced
into the anterior chamber and applied to the posterior stroma
through the injection of an air bubble.-e graft rejection risk is
lower inDMEKwhen compared toDSAEK, and several studies
have demonstrated that DMEK provides faster visual recovery
and better postoperative visual acuity than DSAEK [2–5].
Furthermore, as of today, the rate of primary graft failure after
DMEK seems lower if compared to DSEK [6–8].
Despite the promising outcomes of this new technique,
DMEK is affected by several technical difficulties. In first
instance, the surgical complexity (e.g., because of the thinner
tissue used, graft unfolding can be more challenging) and its
steep learning curve discourage many surgeons from leaving
DSAEK in favor of this technique [9–11]. In addition,
a higher graft detachment rate after DMEK might lead to
more frequent rebubbling or graft repositioning [12]. An-
other problem is primary endothelial cell loss, which seems
to be related to surgeon experience [13]. Loss of endothelial
cells is higher in the early postoperative time after DMEK
and around 7% per year in the following period [14].
Lately, several improvements have been made in the
realization of techniques to isolate and administer human
corneal cells as an alternative to keratoplasty [15]. Emerging
strategies of tissue engineering for corneal endothelial ap-
plications focus on transplantable endothelial cells pro-
duction [16].
Nowadays, cell therapy is focused on culture of corneal
endothelial cells retrieved from donors, followed by grafting
in the donor’s cornea. -e current research is focusing on
the expansion of human corneal endothelial cells to over-
come the shortage of donor tissues [15]; however, bio-
engineered corneal endothelium could lead to promising
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2. Current Findings in Cell Application for
Corneal Endothelial Deficiency
Several studies have been conducted investigating the in
vitro expansion of corneal endothelial cells (CECs) derived
from humans [18, 19] and animal models [20–24]. Human
CECs can be isolated from donor corneas with the appli-
cation of EDTA, trypsin, or collagenase II. Furthermore,
through testing of different culturing factors (such as basal
culture media, additives [25, 26], and methods of media
modulation [25, 27]), several growth environments have
been developed in order to allow the expansion of human
CECs (such as human corneal stroma, collagen, amniotic
membrane, and biodegradable polymers) [28].
As of today, different applicative approaches have been
proposed for human CECs: monolayered cell sheets, cellular
injection therapy, and cell-carrying systems [25]. Localiza-
tion of cultivated human CECs (delivered via intracameral
injection) onto the posterior corneal surface has been tested
through ferromagnetic induction [29, 30] and gravity due to
prone posture [18], or a combination of these methods.
Previous studies from Mimura et al. evaluated the treatment
of corneal endothelial deficiency in rabbit models with
intracameral injection of sphere colonies of corneal endo-
thelial progenitor cells [30]. On the other hand, ultrathin
sheets of human corneal endothelial cells have been trans-
planted with DSAEK devices in animal models. Recently, the
function and clinical adaptability of isolated primary human
corneal endothelial cells have been evaluated in a preclinical
rabbit model of endothelial keratopathy, via a tissue-
engineered endothelial keratoplasty approach, with posi-
tive outcomes regarding corneal thickness reduction [31].
However, this method may prove to be too challenging to be
clinically applicable, since an excessively thin sheet may be
difficult to handle. For this reason, cells injections seemmore
technically feasible. Also, several cell-seeded scaffolds have
been evaluated for corneal transplantation (composed of
different materials such as porcine Descemet’s membrane
[32, 33], chitosan [34], hydrogel lens [35], and paramagnetic
microspheres [36]) promoting transferring of cultivated cells
into target corneas. In accordance with these considerations,
a clinical trial was started in 2013 to investigate the appli-
cation of cultured endothelial cell injections, supplemented
with a ROCK inhibitor (which showed to be useful for
endothelial wound healing [37]) with improvements in
endothelial cell density, corneal thickness reduction, and
visual acuity (UMIN000012534) [38, 39].
3. Stem Cells for Corneal EndotheliumDiseases
Although derivation of human corneal endothelial cells from
embryonic stem cells (with their broad differentiation po-
tential) has been reported [40], several concerns surrounding
the use of this type of stem cells, on the ethical lev-
el—regarding retrieval/donation of oocytes and extraction
from the destruction of embryos—and also in terms of safety
with the high risk of teratoma development, seem to limit its
clinical application [41]. However, a transcriptome analysis
on embryonic-derived endothelial stem cells revealed the
expression of several markers shared with CECs (such as ZO1,
Col8a, and CRY1), with promising perspectives of future
applications of stem cells-derived CECs [42]. Given these
considerations, an impressive effort has been dedicated to the
identification of alternative sources, more suitable for corneal
endothelial cells production.
It has been shown that induced pluripotent stem cells
(iPSCs) extracted frommonkeys can be modified into corneal
endothelial cells (through the use of an endothelium-deriving
medium including GSK-3-beta inhibitor, retinoic acid, and
a ROCK inhibitor) capable of regulating corneal stromal
transparency after transplantation into rabbit eyes [43].
However, relevant matters that currently hinder the use of
iPSCs are the extremely low rate at which adult somatic cells
can be altered in order to obtain iPSCs and the specific
conditions allowing the differentiation of corneal endothelial
cells from human iPSCs, which have not been fully discovered
yet. Taking into consideration also the potential oncogenic
risk related to iPSCs [44], an important work is still required
to perfect iPSCs differentiation before their safe and efficient
application for corneal tissue engineering can be achieved.
Mesenchymal stem cells (MSCs) can be easily obtained
from different human tissues, and their application (similarly
to other pluripotent cell types) seems more feasible if com-
pared to primary human corneal endothelial cells, which have
limited proliferative capacities [45]. As of today, MSCs have
been administered through two different delivery routes: local
(through direct injection or cell-seeded scaffolds) and sys-
temic (intravenous or intra-arterial introduction) [46]. As
multipotent MSCs and iPSCs are derived from adult tissues,
they can be used without the ethical problems surrounding
embryonic stem cells. In addition, autologousMSCs avoid the
need for immune-suppressive drugs to prevent rejection of
allogenic grafts.
-e potential of phenotypical alteration of mesenchymal
stem cells towards human corneal endothelial-like cells is
based on the fact that during eye development in many
species, including humans, corneal endothelial cells differ-
entiate from neural crest-derived periocular mesenchymal
cells (this embryological development is supported also by
several immunohistochemical findings) [47–49]. Moreover,
MSCs and human CECs share some mesenchymal features
(since CECs are able to alter their shape into a fibroblast-like
one and can produce type IV collagen, in presence of FGF and
fibroblastic extracellular matrix [50, 51]) and are able to
express adhesion proteins such ZO1 and N-cadherin [52],
although they are considered as different cell types. However,
as of today, directed differentiation of CECs has not been
clearly identified and the ability to clearly detect a definitive
CEC clone derived from pluripotent or stem cells sources is
still insufficient.
4. Potential Applications of MSCs for
Endothelial Replacement
MSCs open many perspectives for cell-based clinical appli-
cations, due to their regenerating ability and their potential to
differentiate into many different cell types [53, 54]. MSCs can
be easily retrieved from different sources like bone marrow
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(BM-MSC), adipose tissue (AT-MSC), skeletal muscle, dental
pulp, umbilical cord (U-MSCs), and blood from umbilical
cord (UCB-MSCs) [55–62]. However, the ideal source tissue
for endothelial cell differentiation remains to be discovered. In
fact, MSCs derived from different sources show similar
morphology but different colony generation rate, proliferation,
and differentiation capacities. For example, UCB-MSCs
possess the highest differentiation capacity, but the lowest
colony generation frequency, while AT-MSCs have the highest
colony generation frequency and the lowest proliferation
capacity goes to BM-MSCs [63]. Moreover, only a limited
number of MSCs can be extracted from adult tissues (gen-
erally, a 5ml bonemarrow aspiratemay contain between 2,500
and 6,000 MSCs) [64]. Even if this amount may be sufficient
for repairing corneal endothelial lesions, avoiding excessive
manipulation of the cell product, there is not an established
number of cells to initiate the treatment, and the expansion of
MSCs can still be required for clinical application. However,
classical monolayer expansion techniques do not preserve
MSCs progenitor potency, but novel alternativemethods (such
as 3D dynamic cultures, scaffolds, and growth factors appli-
cations and hypoxia modulation) can enhance the efficacy of
expanded cells for clinical application [65].
It has been demonstrated that human BM-MSCs can
differentiate into epithelial corneal cells in vivo and into
corneal keratocytes in vitro and AT-MSCs can differentiate
into epithelial corneal cells in vitro, while human U-MSCs
can differentiate into corneal keratocytes in vivo [66–68]. An
appealing aspect of MSCs is their ability to aim mainly to
injured areas, where they can differentiate into different cell
types in accordance to the surrounding microenvironment
[54]. We had also performed preliminary evaluations,
highlighting the ability of MSCs to survive, migrate, and
integrate at the level of cornea, iris, ciliary body, and lens in
eyes of healthy mice after injection in the anterior chamber
[69] (Figure 1). Moreover, the application of mesenchymal
stem cells, with their high plasticity potential and relative
safety, avoids the ethical and biological concerns related to
the use of embryonic stem cells and iPSCs [70, 71].
-e optimal MSCs delivery strategy for clinical applica-
tion in corneal diseases is represented by local administration
through different methods, since it is also the main technique
currently used for hCECs. Several studies have focused on the
application of mesenchymal stem cells for corneal diseases
treatment. For example, UCB-MSCs have been transplanted
into corneas of mice leading to improved corneal trans-
parency and increased stromal thickness [68], and autologous
bone marrow MSCs have been used to replace corneal en-
dothelium of rabbits in vivo [72]. -ese studies provided
encouraging results, even if the phenotype of implanted cells
was examined using morphological techniques (live confocal
imaging and scanning electron microscopy). Joyce et al. re-
ported that the phenotype of UCB-MSCs could be altered
toward endothelial cell-like cells and that these modified cells
tend to “home” to injured areas of ex-vivo corneal endo-
thelium disease models. Moreover, grafting of these modified
MSCs did not occur onto normal areas of corneal endo-
thelium or Descemet’s membrane, suggesting a high-
specificity action of these cells [73]. Homing of MSCs to
wounded endothelium is probably due to chemotaxis induced
by tumor necrosis factor-α (TNF-α) and expression of ad-
hesion molecules on the surface of endothelial cells (such as
ICAM-1 and ELAM-1), both occurring during inflammation
[74, 75] and promoting migration and adhesion of MSCs in
injured areas [75, 76]. Also, Zo1 and N-cadherin expressions,
used to examine the presence of MSCs, were more distributed
at the level of the damaged area [73]. However the presence,
even if in a smaller quantity, of the same proteins in untreated
cultures raises some doubts regarding the differentiation
process of MSCs into endothelial cells. Moreover, the typical
hexagonal shape of corneal endothelial cells was not observed
in the endothelial-like cells derived from MSCs and the
molecular basis for the complete transition from mesen-
chymal to endothelial type is still not known. Even if further
research is needed to better understand the environmental
conditions leading to an adequate differentiation, MSC can be
considered as a potential candidate for corneal endothelial
cells replacement.
MSCs or endothelial-like cells derived fromMSCs can be
applied with techniques similar to those adopted previously
for other cell types, avoiding the limits of human corneal
endothelial cells, which can’t be expanded indefinitely.
Moreover, MSCs can also be cultivated to create an ultrathin
sheet for endothelial replacement [77], but with implicit
technical difficulties for the surgeon (given the difficult
management). In the light of all these findings, we are
currently evaluating the application of MSCs through
intracameral injection inmurinemodels with twomodalities
(Figure 2): the first one features total asportation of the
diseased endothelium (with Descemet’s membrane sparing),
followed by the injection of a small quantity of mesenchymal
stem cells in the anterior chamber while the other one
features the injection of MSCs without previous endothelial
asportation, with regenerative and repairing intent, espe-
cially at the level of the areas where cell elements are absent.
Both modalities should be carried out with a paralimbal
injection, through a dedicated “ad hoc” syringe, on central
and/or peripheral corneal areas, after the realization in the
anterior chamber of an air-stroma (for the first method) or
air-endothelium (for the latter) interface. It will be possible
to inject a total amount of 1000/2000/5000 MSCs (dispensed
in multiple administrations, three months away from each
other, in relation to cell attachment, migration, and survival
and depending on a case-by-case evaluation). Integration of
MSCs is related to the quantity of injected cells with the
possibility of repeated injections.
5. Discussion and Applicative Aspects
Availability of donors for endothelial keratoplasty is an
emerging problem that must be addressed. Corneal graft
tissue derived from cadavers must meet stringent adequacy
criteria that include serological tests (in selected cases) and
medical history of the donor [78–80]. However, many po-
tential donor corneas, often from elderly donors, are rejected
for transplantation because of their lower endothelial cell
count and possible age-related alterations. Moreover, avail-
ability of corneas can be also affected by cultural, logistical,
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and technical difficulties [81], and long postmortem time or
damage occurred during handling of donor corneas can
possibly lead to unsuitable graft material [82]. -ese are some
of the impelling problems that must be taken into account in
conjunction with global shortage of suitable corneal tissues.
To further alleviate the growing demand for grafting quality
tissue, a considerable clinical interest is being amplified in the
development of tissue engineering as a suitable alternative for
corneal graft [81].
-e application of mesenchymal stem cells for corneal
endothelial replacement can be considered as a promising
perspective, even if its potential still remains to be functionally
assessed with additional studies on in vivo animal models.
First of all, it reduces the need for donor corneas, saving
resources which aremore andmore limited in time.Moreover,
autologous mesenchymal stem cells can be extracted from the
same patient, which can act both as donor and receiving
subject, further lowering rejection rates and immunological
reactions. Since these cells can be injected in the anterior
chamber, technical issues related to surgery are reduced (with
no corneal flap that needs to be carefully managed). Fur-
thermore, repeated injections can be performed, if needed
(such in case of failure or recurrence), after a second cell
extraction or after MSCs expansion (that can function as
a reservoir sample). MSCs adhesion can also be promoted by
coating with antibodies specific for endothelial adhesion
Figure 1: Mesenchymal stem cells introduced in the anterior chamber of murine models can migrate towards the (A) iris, (B) ciliary body, and
(C) lens. Migrated cells (indicated by the arrows in the images on the right) could be observed in the anterior segment for 6 weeks. Images on the
right are highlighted with a filter specific for bisbenzimide, while images on the right are visualized with a filter specific for Dil Stain.
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proteins, improving targeting of MSCs to wounded areas [76].
In addition,MSC injections can prevent endothelial transplant
failure due to cell deciency which can occur in donor corneas
for age-related modications. For this reason, endothelial cell
therapy can be considered also as an adjuvant therapy after
DMEK and not only as a rst-step approach. Autologous
MSCs engraftment can be evaluated in clinical trials on
humans with the additional advantage given by the possibility
of patients prone positioning, which should facilitate their
integration (always preceded by a case-by-case setting). An-
other problem following DMEK andDSAEK is represented by
optical aberrations, due to stromal/donor ap interface. Since
the interface can be signicantly reduced with the application
of mesenchymal stem cells, optical aberration and hyperopic
shift should be avoided.
If a translational approach was promoted, and corneal
endothelial cell engineering was adopted in a widespread
fashion, social and economic costs would be progressively
lowered, with saving of donor corneas, surgical material, and
management expenses. Currently, specic intracellular signals
leading to morphologic changes of MSCs are not known;
hence, further investigation of the molecular basis related to
mesenchymal-to-epithelial transition of MSCs is needed.
Other issues that remain to be addressed before clinical ap-
plication of mesenchymal stem cells for corneal endothelium
replacement are the denition of the best source to obtain
MSCs and best conditions for cell expansion, suppression of
dierentiation to undesired cell types, and homing to damaged
corneal areas. Additional studies, including in vivo testing, are
now needed to identify the specic conditions that would best
support the ability of MSCs to replace corneal endothelial cells
lost due to damage or disease as means of restoring corneal
transparency. Finally, adverse events related to MSCs appli-
cation are rare and often related to the microenvironment in
which MSCs engraft—leading to unwanted dierentiation of
transplanted cells—or the presence of preexisting tumors
whose growth may be promoted by immunosuppression
provided by MSCs [83]. Even if autologous MSCs can be
considered safe in terms of immunogenicity and de-novo
malignancy development [84], long-term clinical trials are
still required to evaluate dierentiation concerns and clinical
ecacy in human corneas.
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